News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 341
- Sources here
- 19
- Companies here
- 18
Search results
Stored financial headlines
Active search
341 matching headlines
Ticker or company: SANAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Form 8K Sanara Medtech Inc For: 11 August By Investing.com
This article reports on the filing of a Form 8K by Sanara Medtech Inc. on August 11, 2026. The brief announcement from Investing.com indicates this as a significant event for shareholders and market watchers of SMTI.
SMTI
main company
Sharemaestro market context
Trend signal active
52 weeks +0.6% · Next-week setup negative 41.2%
MIMEDX Expected to Acquire Sanara MedTech, Pending Closing Conditions
Sanara MedTech reported a 9% increase in Q2 2026 net revenue to $28.1 million and a 14% rise for the first six months to $55.9 million, maintaining a 93% gross margin. The company also announced a signed agreement for its acquisition by MIMEDX, pending …
SMTI
main company
Sharemaestro market context
Trend signal active
52 weeks +0.6% · Next-week setup negative 41.2%
Asana (ASAN) Could Be 42% Below Fair Value On Its AI Work Management Narrative
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Asana (ASAN) is back in focus after recent attention on its AI powered work management tools and hybrid go to market model. This is …
ASAN
main company
Sharemaestro market context
Price above Trend Line
52 weeks -36.8%
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Ford Otomotiv Sanayi AS (FOVSY) (Q2 2026) Earnings Call Highlights: Navigating Inflation ...
This article first appeared on GuruFocus. Revenue: TRY427 billion in the first half of 2026, down 12% versus the inflation-adjusted prior year base. Export Revenue: TRY359 billion, representing 84% of total revenue (up from 82% last year). Domestic Revenue: TRY68 billion, down 21%. Gross …
FROTO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -23.9%
Sana Biotechnology | 10-Q: Quarterly report
This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Sana Biotechnology Q2 Results: Adj. EPS beats estimate
Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results
Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12
Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
USANA Health Sciences Q2 Earnings Call Highlights
USANA Health Sciences (NYSE: USNA) lowered its full-year outlook due to increased digital customer acquisition costs for its Hiya brand and a packaging issue with Rise Wellness, resulting in significant revenue and margin pressure. Despite these challenges, the core nutrition business performed as expected, …
USNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -58.5%
Why Usana Health Sciences Stock Plummeted This Week
Key Points Usana's Q2 earnings came in way below expectations, and sales were also lower than expected. Usana now expects to record a loss for the full-year period. The company also lowered its full-year sales forecast. 10 stocks we like better than USANA Health …
USNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -58.5%
Sana Biotechnology faces earnings test as CAR-T program advances
Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
How Asana Inc. Class A (ASAN) Affects Rotational Strategy Timing
The article analyzes Asana Inc. Class A (ASAN) and its impact on rotational strategy timing, identifying near and mid-term strong sentiment but a weak long-term outlook. It highlights compelling upside potential with no remaining resistance levels above the current price. The analysis includes AI-generated …
ASAN
main company
Sharemaestro market context
Price above Trend Line
52 weeks -36.8%
USANA Health Sciences (NYSE:USNA) Rating Lowered to Strong Sell at Zacks Research
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) to a "strong sell" from "hold," contributing to a consensus "sell" rating for the stock. This follows USANA's recent quarterly report, where the company missed EPS and revenue estimates and issued a lower-than-expected FY2026 EPS guidance. …
USNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -58.5%
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Sana Biotechnology Inc (SANA) has a target price of USD 7.00, with analysts forecasting a potential upside of 151.36%. Based on ratings from 9 analysts, the consensus for SANA stock is a "Buy." The company's EPS for the previous quarter was USD -0.21, and …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
USANA Health Sciences (NYSE:USNA) Cut to "Hold" at Wall Street Zen
USANA Health Sciences (NYSE:USNA) has been downgraded to a "Hold" rating by Wall Street Zen, adding to previous downgrades from other analysts, resulting in an overall consensus rating of "Reduce." This follows the company missing earnings expectations in its latest quarter, reporting an adjusted …
USNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -58.5%